DEXLANSOPRAZOLE PEDIATRIC

DRUG2 trials

Sponsors

Takeda Development Center Americas Inc.

Conditions

Erosive EsophagitisSymptomatic nonerosive GERD in paediatric subjects aged 2 to 11 years

Phase 2

A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease

SuspendedCTIS2022-501349-64-00

Takeda Development Center Americas Inc.Symptomatic nonerosive GERD in paediatric subjects aged 2 to 11 years

Start: 2023-02-01Target: 20Updated: 2025-05-20

A Phase 2, Double-Blind, 36-Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Subjects Aged 2 to 11 Years With EE

Active, not recruitingCTIS2022-501350-11-00

Takeda Development Center Americas Inc.Erosive Esophagitis

Start: 2023-02-01Target: 35Updated: 2025-05-20